LRRK2 and Parkinson disease: Additionally, selective LRRK2 inhibitors demonstrate promise in PD treatment, and further exploration of LRRK2’s molecular role in PD is crucial for developing effective therapies that can enhance patient outcomes and mitigate disease progression (67).